Albinterferon-alfa 2b: A new treatment option for hepatitis C

Expert Opinion on Biological Therapy

Volumn 10, Issue 10, 2010, Pages 1509-1515

  Flisiak, Robert ^a   Flisiak, Iwona ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

HCV; IFN; liver; therapy; viral hepatitis

Indexed keywords

ALBINTERFERON ALPHA2B; ANTIVIRUS AGENT; BLX 883; HUMAN SERUM ALBUMIN; LAMBDA INTERFERON; LOCTERON; OMEGA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; ALBUMINOID; ALPHA2B INTERFERON;

ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ANXIETY; APPETITE; ARTHRALGIA; ASTHENIA; BACKACHE; CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; INTERSTITIAL LUNG DISEASE; MOOD DISORDER; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; DRUG ADMINISTRATION; DRUG COMBINATION; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ALBUMINS; ANIMALS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77956710095     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.521494     Document Type: Review

References (27)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567
2. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008;5:610-622
3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
4. Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opin Investig Drugs 2010;19:63-75
5. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850
6. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838
7. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C [abstract 4]. J Hepatol 2009;50(Suppl 1):S4
8. Lawitz E, Younossi ZM, Shiffman M, et al. Randomized trial comparing systemic and local reactions to controlled-release interferon alpha2b and pegylated-interferon alpha2b in hepatitis C patients who failed prior treatment [abstract 628]. J Hepatol 2009;50(Suppl 1):S231
9. Novozhenov V, Zakharova N, Vinogradova E, et al. Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection [abstract 11]. J Hepatol 2007;46(Suppl 1):S8
10. Lawitz E, Zaman A, Muir AJ, et al. Interim results from a phase Ib dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to eginterferon alfa and ribavirin [abstract 170]. Hepatology 2008;48(Suppl 1):385A
11. Pestka S. The interferons. 50 years after their discovery, there is much more to learn. J Biol Chem 2007;282:20047-20051
12. Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-548
13. Balan V, Nelson DR, Sulkowski MS, et al. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006;11:901-908
14. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972
15. Bain VG, Yoshida EM, Kaita KD, et al. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res 2006;35:256-262
16. Liu C, Zhu H, Subramanian GM, et al. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007;37:941-947
17. Davis GL, Balan V, Sulkowski MS, et al. A phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of escalating doses of a novel recombinant human albumin-interferonalpha fusion protein (albuferon™) in subjects with chronic hepatitis C [abstract 490]. Hepatology 2002;36:285A
18. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-678
19. Balan V, Nelson DR, Sulkowski MS, et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006;11:35-45
20. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-417
21. Bain VG, Kaita KD, Marotta P, et al. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:701-706
22. Human Genome Sciences announces interim results of phase 2b monthly-dosing trial of Zalbin™ in patients with chronic hepatitis C. Nasdaq-HGSI, 24 March 2010
23. Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior non-responders with chronic hepatitis C. Clin Gastro Hepatol 2009;7:212-218
24. Zeuzem S, Sulkowski M, Lawitz E, et al. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment naive, chornic hepatitis C genotype 1 (CHC G1) patients [abstract 1041]. J Hepatol 2009;50(Suppl 1):S377
25. Nelson D, Benhamou Y, Chuang W, et al. Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C [abstract 1042]. J Hepatol 2009;50(Suppl 1):S378
26. Nelson DR, Benhamou Y, Chuang WL, et al. Albinterferon alfa-2b for the treatment of patients with chronic hepatitis C infected with genotypes 2 or 3. Gastroenterology In press Novartis Europharm Ltd withdraws its marketing uthorisation application for Joulferon (albinterferon alfa-2b). EMA/ 249301/2010, 19 April 2010
27. Human Genome Sciences announces preliminary feedback from FDA on Zalbin™ BLA for chronic hepatitis C. Nasdaq-HGSI, 14 June 2010.